Keywords: boehringer, ingelheim, up, stake, cambridge, neuroscience, purchase
Boehringer Ingelheim To Up Stake In Cambridge NeuroScience
Article | 02 September 1996
- Boehringer Ingelheim is to purchase over 1.2 million of Cambridge NeuroScience's common stock at $8.08 per share, thus expanding its investment in ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
